Citi analyst David Lebowitz raised the firm’s price target on BridgeBio (BBIO) to $67 from $58 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Microsoft upgraded, Instacart initiated: Wall Street’s top analyst calls
- Oppenheimer upgrades BridgeBio on execution, data catalysts
- BridgeBio upgraded to Outperform from Perform at Oppenheimer
- BridgeBio Pharma Enters Royalty Purchase Agreement
- Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma’s Path to Profitability